CA2456830A1 - Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse - Google Patents

Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse Download PDF

Info

Publication number
CA2456830A1
CA2456830A1 CA002456830A CA2456830A CA2456830A1 CA 2456830 A1 CA2456830 A1 CA 2456830A1 CA 002456830 A CA002456830 A CA 002456830A CA 2456830 A CA2456830 A CA 2456830A CA 2456830 A1 CA2456830 A1 CA 2456830A1
Authority
CA
Canada
Prior art keywords
particles
mucosal
particle
cap
hsv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002456830A
Other languages
English (en)
Inventor
Steve J. D. Bell
Qing He
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biosante Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2456830A1 publication Critical patent/CA2456830A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Otolaryngology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne la protection immunitaire de la muqueuse, l'administration d'un vaccin pour la muqueuse et l'administration d'un médicament pour la muqueuse. De nouvelles particules à noyau en phosphate de calcium, notamment des nanoparticules, sont utilisées comme adjuvants aux vaccins et comme des compositions destinées à induire l'immunité de protection des muqueuses. L'invention concerne des procédés pour induire une réponse immunitaire à un antigène par l'administration de l'antigène à une surface des muqueuses au moyen des particules de l'invention et des procédés de fabrication de ces particules. Les particules de l'invention peuvent aussi servir à transporter des compositions telles qu'un agent pharmacologique actif jusqu'aux surfaces des muqueuses d'un patient nécessitant un tel traitement; l'invention concerne aussi des procédés pour administrer ces compositions et des procédés pour fabriquer ces particules.
CA002456830A 2001-08-17 2002-08-12 Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse Abandoned CA2456830A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/932,538 2001-08-17
US09/932,538 US20020068090A1 (en) 1999-02-03 2001-08-17 Calcium phosphate particles as mucosal adjuvants
PCT/US2002/025526 WO2003051394A2 (fr) 2001-08-17 2002-08-12 Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse

Publications (1)

Publication Number Publication Date
CA2456830A1 true CA2456830A1 (fr) 2003-06-26

Family

ID=25462469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002456830A Abandoned CA2456830A1 (fr) 2001-08-17 2002-08-12 Particules de phosphate de calcium utilisees comme adjuvants pour la muqueuse

Country Status (7)

Country Link
US (1) US20020068090A1 (fr)
EP (1) EP1418939A2 (fr)
AU (1) AU2002364932A1 (fr)
CA (1) CA2456830A1 (fr)
IL (1) IL160447A0 (fr)
MX (1) MXPA04001509A (fr)
WO (1) WO2003051394A2 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2361421A1 (fr) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
JP2002063917A (ja) * 2000-08-18 2002-02-28 Sony Corp 電気化学デバイス及びその使用方法
US20060062855A1 (en) * 2001-02-27 2006-03-23 Bell Steve J D Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
WO2005072710A2 (fr) * 2004-01-28 2005-08-11 Johns Hopkins University Medicaments et particules de transport de genes se deplaçant rapidement a travers les barrieres muqueuses
BRPI0507680A (pt) * 2004-02-13 2007-07-17 Nod Pharmaceuticals Inc partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
US20060115499A1 (en) * 2004-09-27 2006-06-01 Alk-Abello A/S Liquid allergy vaccine formulation for oromucosal administration
WO2006050368A2 (fr) 2004-11-01 2006-05-11 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium destinees a la medecine esthetique ou cosmetique, et procedes de fabrication et d'utilisation
US20060210590A1 (en) 2005-02-03 2006-09-21 Alk-Abello A/S Minor allergen control to increase safety of immunotherapy
EP1951299B1 (fr) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Vaccins influenza comprenant des combinaisons d'adjuvants particulaires et d'immunopotentiateurs
DE602007012559D1 (de) * 2006-09-08 2011-03-31 Univ Johns Hopkins H die schleimhaut
US20080241256A1 (en) * 2007-03-30 2008-10-02 Liisa Kuhn Targeted active agent delivery system based on calcium phosphate nanoparticles
AU2008339631B2 (en) 2007-12-24 2014-07-24 Novartis Ag Assays for adsorbed influenza vaccines
TWI556839B (zh) 2009-05-06 2016-11-11 研究室護膚股份有限公司 包含活性劑－磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP2844227B1 (fr) 2012-05-03 2020-11-18 Kala Pharmaceuticals, Inc. Nanoparticles pharmaceutiques montrant du transport mucosale amélioré
EP4008355A1 (fr) 2012-05-03 2022-06-08 Kala Pharmaceuticals, Inc. Nanoparticules pharmaceutiques permettant un transport muqueux amélioré
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
GB201318858D0 (en) * 2013-10-25 2013-12-11 Glaxosmithkline Biolog Sa Calcium fluoride compositions
US11110064B2 (en) * 2018-12-16 2021-09-07 SRM Institute of Science and Technology Gel formulation for treating diabetic foot ulcer infections
WO2022031594A1 (fr) * 2020-08-06 2022-02-10 Dianomi Therapeutics, Inc. Compositions et méthodes d'administration de vaccins
CN114181102B (zh) * 2021-11-10 2023-06-23 深圳市检验检疫科学研究院 己雷琐辛半抗原、人工抗原、抗体及其合成方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU407324B2 (en) * 1962-05-01 1970-10-28 Smith, Kline & French Laboratories Powdered silicone products and processes
US4070454A (en) * 1973-05-04 1978-01-24 Agence Nationale De Valorisation De La Recherche (Anvar) Vaccines, the process for preparing the same and the applications thereof
FR2227861B1 (fr) * 1973-05-04 1976-07-02 Anvar
FR2522269A1 (fr) * 1982-02-26 1983-09-02 Pasteur Institut Agents antitumoraux, tels que la daunorubicine, a efficacite amelioree, leur obtention et procede pour augmenter l'efficacite des agents antitumoraux
FR2577048B1 (fr) * 1985-02-05 1988-05-06 Pasteur Institut Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application
IL88961A (en) * 1988-01-29 1992-07-15 Basf Ag Stable mixtures containing oxidation-sensitive compounds
NO168615C (no) * 1989-10-17 1992-03-11 Datalab Oy Fremgangsmaate og anordning for gjenkjenning av en mynt
US5469599A (en) * 1993-10-27 1995-11-28 Wurdack; Roy A. Slide
DE4444052A1 (de) * 1994-12-10 1996-06-13 Rhone Poulenc Rorer Gmbh Pharmazeutische, oral anwendbare Zubereitung
US8333996B2 (en) * 1995-05-19 2012-12-18 Etex Corporation Calcium phosphate delivery vehicle and adjuvant
US5648097A (en) * 1995-10-04 1997-07-15 Biotek, Inc. Calcium mineral-based microparticles and method for the production thereof
US6210715B1 (en) * 1997-04-01 2001-04-03 Cap Biotechnology, Inc. Calcium phosphate microcarriers and microspheres
CA2361421A1 (fr) * 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Particules therapeutiques de phosphate de calcium et procedes de fabrication et d'utilisation associes

Also Published As

Publication number Publication date
AU2002364932A8 (en) 2003-06-30
WO2003051394A2 (fr) 2003-06-26
WO2003051394A3 (fr) 2003-12-24
MXPA04001509A (es) 2004-06-03
AU2002364932A1 (en) 2003-06-30
IL160447A0 (en) 2004-07-25
US20020068090A1 (en) 2002-06-06
EP1418939A2 (fr) 2004-05-19

Similar Documents

Publication Publication Date Title
US20020068090A1 (en) Calcium phosphate particles as mucosal adjuvants
EP1150918B1 (fr) Procede de fabrication de particules therapeutiques de phosphate de calcium
Jin et al. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines
Alpar et al. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery
Sokolova et al. The potential of nanoparticles for the immunization against viral infections
CN111375055B (zh) 一种2019-nCoV亚单位疫苗组合物及其免疫方法
EP0812209B1 (fr) Vehicles cochleaires utilises dans l'administration de molecules biologiquement utiles
Moyle et al. Mucosal immunisation: adjuvants and delivery systems
AU771205B2 (en) Novel, non-antigenic, mucosal adjuvant formulation which modulates the effects of substances, including vaccine antigens, in contact with mucosal body surfaces
CA2169297C (fr) Vaccins a base de cochleate proteique ou peptidique et procedes d'immunisation faisant appel a ces vaccins
JP2002540076A (ja) ワクチン組成物
JP6122083B2 (ja) ナノエマルションワクチン
US20060165722A1 (en) Peptides for delivery of mucosal vaccines
US9585954B2 (en) Mucosal immunization
JP2003535017A5 (fr)
US20060062855A1 (en) Therapeutic calcium phosphate particles for use in inhibiting expression of a gene
AU2005244128A1 (en) Pulmonary malarial vaccine
EP1471034A2 (fr) Particules thérapeutiques de phosphate de calcium et procédés de fabrication et d'utilisation
JP4944335B2 (ja) 粘膜表面へ投与するための医薬組成物
Gebril Development of a mucosal vaccine delivery system
Li Immunization with synthetic nanoparticles to generate mucosal CD8 T Cell responses

Legal Events

Date Code Title Description
FZDE Discontinued